$INVA Income Statement | Understand Stock

$INVA

$20.96 -$0.10 (0.45%) Live

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenue
Royalty Revenue
Revenue from collaborative arrangements
Net product sales
License revenue
License and other revenue
Total revenue

Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding amortization of intangible assets)
Cost of license revenue
Amortization of acquired intangible assets
Gross profit
Operating expenses:
Selling, general and administrative
Research and development
General and administrative
Amortization of acquired intangible assets
Gain on sale of Theravance Respiratory Company, LLC ("TRC")
Loss on extinguishment of debt
Total operating expenses
Income from operations

Changes in fair values of equity method investments, net
Changes in fair values of equity and long-term investments, net
Interest and dividend income
Interest expense
Realized gain on equity investments
Other expense, net
Total expenses, net
Income before provision for income taxes
Income tax expense, net
Net income and comprehensive income
Net loss attributable to noncontrolling interests
Net income attributable to Innoviva stockholders
Net income per share:
Basic
Diluted
Shares used to compute net income per share:
Basic
Diluted

Comments